Cell-based immunotherapy called CAR-T cell therapy has revolutionized the treatment of several cancers. The treatment uses genetically modified T cells to target and attack certain types of leukemia and lymphoma. While it can eliminate cancer in some patients who would otherwise succumb to the disease, it also comes with the risk of a range of side effects, some of which affect brain function and can be life-threatening.
A new study from Washington University School of Medicine in St. Louis suggests a simple blood test — administered before CAR-T cell treatment is initiated — may identify which patients are predisposed to developing neurotoxic side effects in the days and weeks after CAR-T cell therapy. Analyzing blood samples from patients before, during and after CAR-T cell therapy, the researchers found that levels of a protein called neurofilament light chain (NfL) are higher in patients who go on to develop neurotoxic complications. High levels of the protein are present even before therapy begins, and those levels remain elevated throughout treatment and up to a month afterward.
The research, published Sept. 1 in the journal JAMA Oncology, could help doctors anticipate these life-threatening side effects and allow them to begin giving treatments that can reduce the neurotoxic effects early during a patient’s treatment. It also opens the door to developing ways to prevent the side effects or reduce their risk before CAR-T cell therapy begins.
“Our study suggests that some patients receiving CAR-T cell therapy have previously undetected damage to neurons present at baseline, before we even begin preparing them for this treatment,” said lead author Omar H. Butt, MD, PhD, an instructor in medicine who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. “We don’t know the origin of this damage, but it appears to predispose them to developing neurotoxic complications. If we understand who is at risk of these complications, we can take early steps to prevent it or reduce the severity.”
A general marker of damage to neurons, the NfL protein has been used to measure or monitor the severity of several neurologic diseases, including Alzheimer’s disease and multiple sclerosis.
“Measures of NfL in the blood are being used as a way to evaluate the effectiveness of potential new therapies for multiple sclerosis,” said co-senior author Beau M. Ances, MD, PhD, the Daniel J. Brennan Professor of Neurology. “We plan to continue our studies to find the origin of neuronal damage in these cancer patients. This is a unique collaboration that was possible at Washington University because we have some of the top experts in CAR-T cell therapy and leading expertise in neurodegenerative diseases. It presents a great opportunity to bridge gaps and bring these fields together to try to solve a vexing problem and help patients.”
The study was relatively small, involving 30 patients treated at Siteman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University in Cleveland.
The baseline levels of NfL could distinguish patients who did not develop neurotoxic side effects from those who developed any degree of such side effects. The researchers plan to continue analyzing data from more patients to see if a larger sample size will allow them to identify patients at risk of mild, moderate or severe complications.
The complications vary widely across individuals, and can include anything from difficulty concentrating, memory problems, confusion, difficulty reading, and headaches to seizures, strokes and brain swelling. Doctors manage these complications mainly with high-dose steroids and sometimes with immune modulating treatments that attempt to reduce inflammation. It is extremely helpful to know who is at risk of the most dangerous side effects since these therapies can, unfortunately, blunt the anti-cancer effect of the CAR-T cells, and doctors would prefer to avoid using them whenever possible.
Another mystery is that the elevated NfL levels are present beforehand and remain mostly stable even as some patients develop and then recover from neurotoxic side effects. This suggests that NfL levels indicate something is wrong but don’t reflect whatever is taking place to cause the patients’ complications.
“We’re just seeing the tip of the iceberg in terms of the actual disease process, and that’s where many of our future studies are going,” Butt said. “We’re trying to get a better sense of what is causing these changes to begin with. And in later stages, even after symptoms have resolved, we still see these elevated NfL levels.”
Added co-senior author Armin Ghobadi, MD, an associate professor of medicine and clinical director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine and Siteman Cancer Center: “We have a study ongoing at Siteman to see if, in fact, these patients continue to have subtle symptoms in terms of cognitive changes or deficits that persist long term.”
Butt, Ances, Ghobadi and co-author John F. DiPersio, MD, PhD, report a provisional patent pending on the use of plasma NfL as a predictive biomarker for immune effector cell-associated neurotoxicity syndrome (ICANS).
This work was supported by the McDonnell Center for Systems Neuroscience at Washington University in St. Louis, grant number 22-3922-26239A; the Institute of Clinical and Translational Sciences through the Clinical and Translational Research Funding Program at Washington University in St. Louis, grant number P18-03173-17; the Paula and Rodger O. Riney Fund; the Daniel J. Brennan MD Fund; the Fred Simmons and Olga Mohan Fund; the National Cancer Institute (NCI) of the National Institutes of Health (NIH), grant number R35 CA210084; an NCI Outstanding Investigator Award to John F. DiPeriso, grant number RG-1802-30253; the National Multiple Sclerosis Society; and the National Institute of Neurological Disorders and Stroke, grant number R01NS106289.
Butt OH, et al. Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome. JAMA Oncology. Sept. 1, 2022.
About Washington University School of Medicine
WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,700 faculty. Its National Institutes of Health (NIH) research funding portfolio is the fourth largest among U.S. medical schools, has grown 54% in the last five years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,790 faculty physicians practicing at over 60 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.
Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.